Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Blue Earth Therapeutics Ltd
Pathos AI, Inc.
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
K36 Therapeutics, Inc.
Atavistik Bio, Inc
Dana-Farber Cancer Institute
RenJi Hospital
Eli Lilly and Company
The Netherlands Cancer Institute
University of California, San Francisco
NiKang Therapeutics, Inc.
University of Miami
The Netherlands Cancer Institute
Ottawa Hospital Research Institute
Marengo Therapeutics, Inc.
Lipac Oncology LLC
Eli Lilly and Company
Advanced Accelerator Applications
Endocyte
Stanford University
Novartis
Algemeen Ziekenhuis Maria Middelares
Poseida Therapeutics, Inc.
Sharp HealthCare
University Teaching Hospital Hall in Tirol
Regina Elena Cancer Institute
VA Greater Los Angeles Healthcare System
Mayo Clinic
Promontory Therapeutics Inc.
Steba Biotech S.A.
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Aragon Pharmaceuticals, Inc.
NanOlogy, LLC
Region Skane
Medipol University
NanOlogy, LLC
British Columbia Cancer Agency
Tianjin Medical University Second Hospital
RenJi Hospital
Herlev and Gentofte Hospital
Advanced Accelerator Applications
Steba Biotech S.A.
Tampere University Hospital
Azienda Ospedaliero-Universitaria di Modena
M.D. Anderson Cancer Center
Celldex Therapeutics
NanOlogy, LLC